| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Friedrich Miescher Institute, CH-4002 Basel, Switzerland
Interleukin (IL)-6, a multifunctional regulator of immune response, hematopoiesis, and acute phase reactions, has also been shown to regulate cancer cell proliferation. We have investigated IL-6 signaling pathways and cellular responses in the T47D breast carcinoma cell line. The IL-6-type cytokines, IL-6 and oncostatin M, simultaneously inhibited cell proliferation and increased cell migration. In T47D cells, IL-6 stimulated the activation of Janus-activated kinase 1 tyrosine kinase and signal transducers and activators of transcription (STAT) 1 and STAT3 transcription factors. Expression of dominant negative STAT3 in the cells strongly reduced IL-6-mediated growth inhibition but did not prevent IL-6induced cell migration. IL-6 treatment led to activation of the mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 3'-kinase (PI3K) pathways. Inhibition of MAPK or PI3K activity reversed IL-6- and oncostatin M-stimulated migration. Because cross-talk between cytokine receptors and members of the ErbB family of receptor tyrosine kinases has been described previously, we have examined their interaction in T47D cells. Down-regulation of ErbB receptor activity, through the use of specific pharmacological inhibitors or dominant negative receptor constructs, revealed that IL-6-induced MAPK activation was largely dependent on epidermal growth factor (EGF) receptor activity, but not on ErbB-2 activity. Using a monoclonal antibody that interferes with EGF receptor-ligand interaction, we have shown that in T47D cells, IL-6 cooperates with an EGF receptor autocrine activity loop for signaling through the MAPK and PI3K pathways and for cell migration. Both the tyrosine phosphatase SHP-2 and the multisubstrate docking molecule Gab1, which are potential links between IL-6 and the MAPK/PI3K pathways, were constitutively associated with the active EGF receptor. On IL-6 stimulation, SHP-2 and Gab1 were recruited to the gp130 subunit of the IL-6 receptor and tyrosine phosphorylated, allowing downstream signaling to the MAPK and PI3K pathways. Thus, in T47D breast carcinoma cells, IL-6 acts in synergy with EGF receptor autocrine activity to signal through the MAPK/PI3K pathways. Cooperation between IL-6 and the EGF receptor in T47D breast carcinoma cells illustrates how a combination of multiple stimuli, either exogenous or endogenous, may result in synergistic cellular responses.
This article has been cited by other articles:
|
|
 |
|
  N. Underhill-Day and J. K. Heath Oncostatin M (OSM) Cytostasis of Breast Tumor Cells: Characterization of an OSM Receptor {beta}-Specific Kernel. Cancer Res., November 15, 2006; 66(22): 10891 - 10901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J.F. de Wolf, R. M.J. Cupers, R. M. Bertina, and H. L. Vos Interleukin-6 Induction of Protein S Is Regulated Through Signal Transducer and Activator of Transcription 3 Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 2168 - 2174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Takaki, Y. Minoda, K. Koga, G. Takaesu, A. Yoshimura, and T. Kobayashi TGF-beta1 suppresses IFN-gamma-induced NO production in macrophages by suppressing STAT1 activation and accelerating iNOS protein degradation. Genes Cells, August 1, 2006; 11(8): 871 - 882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Chae, M.-S. Ha, D.-H. Yun, H.-O. Pae, H.-T. Chung, S.-W. Chae, Y.-K. Jung, and H.-R. Kim Mechanism of Cyclosporine-induced Overgrowth in Gingiva. J. Dent. Res., June 1, 2006; 85(6): 515 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ueno, S. Saito, T. Wada, K. Yamaguchi, M. Satoh, Y. Arai, and T. Miyagi Plasma Membrane-associated Sialidase Is Up-regulated in Renal Cell Carcinoma and Promotes Interleukin-6-induced Apoptosis Suppression and Cell Motility J. Biol. Chem., March 24, 2006; 281(12): 7756 - 7764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Igaz, R. Salvi, J.-P. Rey, M. Glauser, F. P. Pralong, and R. C. Gaillard Effects of Cytokines on Gonadotropin-Releasing Hormone (GnRH) Gene Expression in Primary Hypothalamic Neurons and in GnRH Neurons Immortalized Conditionally Endocrinology, February 1, 2006; 147(2): 1037 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Queen, R. E. Ryan, R. G. Holzer, C. R. Keller-Peck, and C. L. Jorcyk Breast Cancer Cells Stimulate Neutrophils to Produce Oncostatin M: Potential Implications for Tumor Progression Cancer Res., October 1, 2005; 65(19): 8896 - 8904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. E. Avissar, L. Toia, and H. C. Sax Epidermal Growth Factor and/or Growth Hormone Induce Differential, Side-Specific Signal Transduction Protein Phosphorylation in Enterocytes JPEN J Parenter Enteral Nutr, September 1, 2005; 29(5): 322 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Hefler, C. Grimm, T. Lantzsch, D. Lampe, S. Leodolter, H. Koelbl, G. Heinze, A. Reinthaller, D. Tong-Cacsire, C. Tempfer, et al. Interleukin-1 and Interleukin-6 Gene Polymorphisms and the Risk of Breast Cancer in Caucasian Women Clin. Cancer Res., August 15, 2005; 11(16): 5718 - 5721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Weidt, B. Niggemann, W. Hatzmann, K. S. Zanker, and T. Dittmar Differential Effects of Culture Conditions on the Migration Pattern of Stromal Cell-Derived Factor-Stimulated Hematopoietic Stem Cells Stem Cells, November 1, 2004; 22(6): 890 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Selander, L. Li, L. Watson, M. Merrell, H. Dahmen, P. C. Heinrich, G. Muller-Newen, and K. W. Harris Inhibition of gp130 Signaling in Breast Cancer Blocks Constitutive Activation of Stat3 and Inhibits in Vivo Malignancy Cancer Res., October 1, 2004; 64(19): 6924 - 6933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Schick, E. J. Oakeley, N. E. Hynes, and A. Badache TEL/ETV6 Is a Signal Transducer and Activator of Transcription 3 (Stat3)-induced Repressor of Stat3 Activity J. Biol. Chem., September 10, 2004; 279(37): 38787 - 38796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Mahtouk, M. Jourdan, J. De Vos, C. Hertogh, G. Fiol, E. Jourdan, J.-F. Rossi, and B. Klein An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis Blood, March 1, 2004; 103(5): 1829 - 1837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Bliskovsky, E. S. Ramsay, J. Scott, W. DuBois, W. Shi, S. Zhang, X. Qian, D. R. Lowy, and B. A. Mock Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene PNAS, December 9, 2003; 100(25): 14982 - 14987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. DeMichele, A.-M. Martin, R. Mick, P. Gor, L. Wray, M. Klein-Cabral, G. Athanasiadis, T. Colligan, E. Stadtmauer, and B. Weber Interleukin-6 -174G->C Polymorphism Is Associated with Improved Outcome in High-Risk Breast Cancer Cancer Res., November 15, 2003; 63(22): 8051 - 8056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Trikha, R. Corringham, B. Klein, and J.-F. Rossi Targeted Anti-Interleukin-6 Monoclonal Antibody Therapy for Cancer: A Review of the Rationale and Clinical Evidence Clin. Cancer Res., October 15, 2003; 9(13): 4653 - 4665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Lee, R. Schiff, X. Cui, D. Sachdev, D. Yee, A. P. Gilmore, C. H. Streuli, S. Oesterreich, and D. L. Hadsell New Mechanisms of Signal Transduction Inhibitor Action: Receptor Tyrosine Kinase Down-Regulation and Blockade of Signal Transactivation Clin. Cancer Res., January 1, 2003; 9(1): 516S - 523S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhao, J. J. Melenhorst, and L. Hennighausen Loss of Interleukin 6 Results in Delayed Mammary Gland Involution: A Possible Role for Mitogen-Activated Protein Kinase and Not Signal Transducer and Activator of Transcription 3 Mol. Endocrinol., December 1, 2002; 16(12): 2902 - 2912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Motoyama, N. E. Hynes, and H. A. Lane The Efficacy of ErbB Receptor-targeted Anticancer Therapeutics Is Influenced by the Availability of Epidermal Growth Factor-related Peptides Cancer Res., June 1, 2002; 62(11): 3151 - 3158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Hutt and J. W. DeWille Oncostatin M Induces Growth Arrest of Mammary Epithelium via a CCAAT/enhancer-binding Protein {delta}-dependent Pathway Mol. Cancer Ther., June 1, 2002; 1(8): 601 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Alberich Jorda, S. E. Verbakel, P. J. M. Valk, Y. V. Vankan-Berkhoudt, M. Maccarrone, A. Finazzi-Agro, B. Lowenberg, and R. Delwel Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol Blood, April 15, 2002; 99(8): 2786 - 2793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Horsch, M. D. Schaller, and N. E. Hynes The Protein Tyrosine Phosphatase-PEST Is Implicated in the Negative Regulation of Epidermal Growth Factor on PRL Signaling in Mammary Epithelial Cells Mol. Endocrinol., December 1, 2001; 15(12): 2182 - 2196. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
